Predicting Hemorrhagic Transformation of Acute Ischemic Stroke

AbstractHemorrhagic transformation (HT) increases the morbidity and mortality of ischemic stroke. Anticoagulation is often indicated in patients with atrial fibrillation, low ejection fraction, or mechanical valves who are hospitalized with acute stroke, but increases the risk of HT. Risk quantification would be useful. Prior studies have investigated risk of systemic hemorrhage in anticoagulated patients, but none looked specifically at HT. In our previously published work, age, infarct volume, and estimated glomerular filtration rate (eGFR) significantly predicted HT. We created the hemorrhage risk stratification (HeRS) score based on regression coefficients in multivariable modeling and now determine its validity in a prospectively followed inpatient cohort.A total of 241 consecutive patients presenting to 2 academic stroke centers with acute ischemic stroke and an indication for anticoagulation over a 2.75-year period were included. Neuroimaging was evaluated for infarct volume and HT. Hemorrhages were classified as symptomatic versus asymptomatic, and by severity. HeRS scores were calculated for each patient and compared to actual hemorrhage status using receiver operating curve analysis.Area under the curve (AUC) comparing predicted odds of hemorrhage (HeRS score) to actual hemorrhage status was 0.701. Serum glucose (P < 0.001), white blood cell count (P < 0.001), and warfarin use prior to admission (P = 0.002) were also associated with HT in the validation cohort. With these variables, AUC improved to 0.854. Anticoagulation did not significantly increase HT; but with higher intensity anticoagulation, hemorrhages were more likely to be symptomatic and more severe.The HeRS score is a valid predictor of HT in patients with ischemic stroke and indication for anticoagulation.

[1]  A. Hillis,et al.  Predicting Symptomatic Intracerebral Hemorrhage Versus Lacunar Disease in Patients With Longstanding Hypertension , 2014, Stroke.

[2]  Askiel Bruno,et al.  The Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Protocol: A Randomized, Blinded, Efficacy Trial of Standard vs. Intensive Hyperglycemia Management in Acute Stroke , 2014, International journal of stroke : official journal of the International Stroke Society.

[3]  A. Hillis,et al.  Serum Creatinine May Indicate Risk of Symptomatic Intracranial Hemorrhage After Intravenous Tissue Plasminogen Activator (IV tPA) , 2013, Medicine.

[4]  A. Hillis,et al.  Hemorrhagic transformation in patients with acute ischaemic stroke and an indication for anticoagulation , 2013, European journal of neurology.

[5]  G. Jickling,et al.  Breaking down barriers to identify hemorrhagic transformation in ischemic stroke , 2012, Neurology.

[6]  L. Køber,et al.  Stroke and bleeding in atrial fibrillation with chronic kidney disease. , 2012, The New England journal of medicine.

[7]  Robby Nieuwlaat,et al.  Revised A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in atrial fibrillation patients: The Euro Heart Survey , 2012 .

[8]  G. Rosenberg,et al.  Blood-brain barrier breakdown in acute and chronic cerebrovascular disease. , 2011, Stroke.

[9]  K. Nakashima,et al.  [The Rotterdam study]. , 2011, Nihon rinsho. Japanese journal of clinical medicine.

[10]  A. Hillis,et al.  ABC/2: estimating intracerebral haemorrhage volume and total brain volume, and predicting outcome in children , 2011, Developmental medicine and child neurology.

[11]  D. Tanné,et al.  Chronic Kidney Disease in Patients with Acute Intracerebral Hemorrhage: Association with Large Hematoma Volume and Poor Outcome , 2010, Cerebrovascular Diseases.

[12]  Gregory Y H Lip,et al.  A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.

[13]  B. Psaty,et al.  Intravenous tissue plasminogen activator and stroke in the elderly. , 2010, The American journal of emergency medicine.

[14]  J. Stephenson,et al.  Retrospective study of total healthcare costs associated with chronic nonvalvular atrial fibrillation and the occurrence of a first transient ischemic attack, stroke or major bleed , 2009, Current medical research and opinion.

[15]  J. Broderick,et al.  Warfarin use leads to larger intracerebral hematomas , 2008, Neurology.

[16]  Sumit R. Majumdar,et al.  Admission Hyperglycemia Predicts a Worse Outcome in Stroke Patients Treated With Intravenous Thrombolysis , 2008, Diabetes Care.

[17]  A. Hofman,et al.  Decreased Glomerular Filtration Rate Is a Risk Factor for Hemorrhagic But Not for Ischemic Stroke: The Rotterdam Study , 2007, Stroke.

[18]  J. Broderick,et al.  Intracranial Hemorrhage Associated With Revascularization Therapies , 2007, Stroke.

[19]  M. Rich,et al.  Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). , 2006, American heart journal.

[20]  G. Remuzzi,et al.  Platelet dysfunction in renal failure. , 2004, Seminars in thrombosis and hemostasis.

[21]  S. Greenberg,et al.  Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage , 2004, Neurology.

[22]  L. Goldstein,et al.  Anticoagulants and antiplatelet agents in acute ischemic stroke: Report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a Division of the American Heart Association) , 2002, Neurology.

[23]  J. Riancho,et al.  Stroke severity in patients with atrial fibrillation. , 2002, The American journal of medicine.

[24]  Erich Bluhmki,et al.  Risk Factors for Severe Hemorrhagic Transformation in Ischemic Stroke Patients Treated With Recombinant Tissue Plasminogen Activator: A Secondary Analysis of the European-Australasian Acute Stroke Study (ECASS II) , 2001, Stroke.

[25]  L Bozzao,et al.  Hemorrhagic transformation within 36 hours of a cerebral infarct: relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort. , 1999, Stroke.

[26]  A. Levey,et al.  A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.

[27]  Pellegrino Tr Anticoagulants and antiplatelet agents in acute ischemic stroke. , 1998 .

[28]  E. Boulanger,et al.  Erythrocyte sedimentation rate, an underestimated tool in chronic renal failure. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[29]  G. Sette,et al.  Hemorrhagic transformation of brain infarct , 1996, Neurology.

[30]  Koroshetz Wj,et al.  Tissue plasminogen activator for acute ischemic stroke. , 1996, The New England journal of medicine.

[31]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[32]  K. Iseki,et al.  Evidence for high risk of cerebral hemorrhage in chronic dialysis patients. , 1993, Kidney international.

[33]  W. Mcdonald,et al.  Patterns of blood-brain barrier breakdown in inflammatory demyelination. , 1991, Brain : a journal of neurology.

[34]  C. Hornig,et al.  Hemorrhagic cerebral infarction--a prospective study. , 1986, Stroke.

[35]  G. Di Minno,et al.  Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. , 1985, The American journal of medicine.

[36]  J. Innes,et al.  The significance of gross elevations of the erythrocyte sedimentation rate in a general medical unit , 1979, European journal of clinical investigation.